Search for dissertations about: "Bortezomib"
Showing result 1 - 5 of 30 swedish dissertations containing the word Bortezomib.
-
1. New Molecular Approaches to Glioblastoma Therapy
Abstract : Glioblastoma (GBM) is the most common high-grade brain tumor diagnosed in patients who are more than 50 years of age. The standard of care treatment is surgery, followed by radiotherapy and chemotherapy. The median life expectancy of patients is only between 12 to 15 months after receiving current treatment regimes. READ MORE
-
2. Identification and characterization of a proteasome deubiquitinase inhibitor
Abstract : The 26S proteasome has emerged as an attractive therapeutic target in the treatment of cancers. Proteasome inhibitors have been shown to selectively kill cancer cells. The FDA approval of bortezomib for the treatment of multiple myeloma and mantle cell lymphoma has clinically validated the 26S proteasome as a therapeutic target in oncology. READ MORE
-
3. Effects of proteasome inhibitors on chondrogenesis and linear bone growth
Abstract : Linear bone growth occurs at the growth plate, a thin layer of cartilage between the epiphysis and metaphysis of long bones. In the growth plate, resting/stem-like chondrocytes divide and generate the highly proliferative chondrocytes, which further differentiate into the enlarged hypertrophic form before being substituted by bone, a process called endochondral ossification. READ MORE
-
4. Studies of b-AP15 : a novel inhibitor of proteasome deubiquitinase activity
Abstract : Bortezomib was the first FDA approved proteasome inhibitor that was initially very successful in treatment of multiple myeloma patients but acquired resistance and adverse side-effect highly decreased patients’ quality of life. Development of 2nd generation proteasome inhibitors that could overcome these shortcomings is thus of prime medical importance. READ MORE
-
5. Proteasome inhibition in the regulation of natural killer cell function and multiple myeloma cell apoptosis
Abstract : Multiple myeloma (MM) is a hematologic malignancy mostly occurring in the elderly and characterized by an expansion of monoclonal plasma cells in the bone marrow and increased monoclonal immunoglobulin in plasma. The outcome of this disease has been greatly improved due to introduction of new drugs. READ MORE
